C4 Therapeutics CCCC Cash Flow Statement (2019-2026)

NASDAQ CCCC
$3.17 +0.01 (+0.47%)
As of: Oct 21, 2026 · 2:46 PM EDT
Reported Financials

C4 Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

C4 Therapeutics reported cash from operations of -$1.57M and free cash flow of -$1.61M for the quarter ended Jun 2026, up 86.9% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-24.68M-15.67M-31.62M-27.41M-31.96M-37.20M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.49M-25.13M-23.64M
Depreciation and DepletionDep. & Depletion
0.33M0.32M0.31M0.44M0.42M0.52M0.55M0.46M0.45M0.13M0.38M0.30M0.37M0.36M0.36M0.42M0.38M0.38M0.36M0.34M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.18M0.18M0.18M0.18M0.18M0.18M0.18M0.18M0.05M
Depreciation & Amortization (CF)Dep. & Amort.
0.33M0.32M0.31M0.44M0.42M0.52M0.55M0.46M0.45M0.43M0.45M0.45M0.44M0.48M0.46M0.62M0.46M0.43M0.40M0.29M
Share-based CompensationStock Comp.
6.09M6.35M8.94M8.15M6.01M6.92M6.25M6.43M8.20M6.36M6.22M6.38M8.83M8.24M5.51M4.99M4.59M4.01M2.67M3.04M
Gains from Sales and DivestituresGains Divest
Asset Writedowns and ImpairmentWritedown
10.73M
Other non-cash itemsOther Non-Cash
0.33M0.44M1.18M1.71M1.50M1.52M1.53M0.62M1.56M1.58M1.60M1.63M1.65M1.67M1.69M1.43M1.44M1.45M
Change in Working Capital
Change in ReceivablesChange Receivables
-1.37M0.87M-3.94M-0.06M-0.22M-0.02M-0.95M0.50M-0.53M11.30M1.80M-12.43M9.17M-7.24M4.93M-5.83M4.34M-4.14M0.48M-1.55M
Change in Account PayablesChange Payables
-0.60M0.76M-1.15M0.59M-1.69M-1.08M-0.14M1.08M-0.84M0.17M0.18M-0.72M0.59M-0.18M-0.65M1.53M-0.89M-0.47M-0.09M0.35M
Change in Accured ExpensesChange Accured Exp.
1.93M2.14M-3.77M3.68M2.48M2.69M-3.67M0.54M-0.73M5.18M-7.66M-1.75M4.17M3.98M-6.73M0.63M-2.02M2.07M-3.52M3.99M
Change in Other Operating AssetsOther Assets Change
-0.06M5.00M-0.31M-1.41M1.51M-0.17M-0.50M-1.60M0.69M-1.32M4.67M0.45M-0.82M0.03M-0.34M-3.63M0.57M2.26M-0.12M1.66M
Change in Other Operating LiabilitiesOther Liabilities Change
-3.92M-15.18M-5.58M-11.41M-3.71M-2.46M-3.86M6.66M-11.76M8.03M17.31M-3.65M-5.40M-3.59M-1.86M-4.37M-8.22M-10.16M-4.31M13.22M
Other Working Capital ChangesOther WC Changes
-3.86M-20.17M-5.27M-10.00M-5.22M-2.29M-3.36M8.26M-12.45M9.35M12.64M-4.10M-4.59M-3.62M-1.52M-0.74M-8.79M-12.42M-4.18M11.56M
Other Operating ActivitiesOther Ops.
0.03M0.04M0.05M-0.04M-0.09M0.11M0.03M-0.05M0.03M0.02M0.03M0.02M0.03M0.01M
Cash from OperationsCash from Ops.
-18.36M-25.67M-26.60M-22.20M-28.02M-29.13M-33.13M-19.00M-30.71M-24.01M-18.12M-4.97M-24.13M-17.93M-33.29M-12.06M-31.21M-22.15M-29.94M-1.57M
Investing Activities
Capital ExpendituresCapex
0.11M0.17M0.53M3.31M1.49M0.59M0.36M0.60M0.16M0.20M-0.01M0.00M0.19M0.41M0.01M0.06M0.04M
Change in Property, Plant and EquipmentChange in PP&E
-0.11M-0.17M-0.53M-3.31M-1.49M-0.59M-0.36M-0.60M-0.16M-0.20M0.01M0.00M-0.19M-0.41M-0.01M-0.06M-0.04M
Purchase of InvestmentsInvestments Purchased
154.70M145.42M76.22M31.91M55.11M56.29M11.44M48.64M31.94M37.88M107.75M67.22M68.57M40.78M25.64M21.68M46.68M133.07M40.81M70.83M
Sale and Maturity of InvestmentsInvestments Sold
54.08M86.11M72.39M65.67M78.33M67.06M65.56M64.15M90.27M69.98M54.35M55.72M68.71M54.45M54.77M60.79M51.18M52.35M57.03M56.05M
Cash from Investing ActivitiesCash from Investing
-100.63M-59.41M-4.00M33.23M19.91M9.28M53.53M15.15M57.73M31.95M-53.40M-11.71M0.16M13.67M29.13M38.92M4.09M-80.73M16.15M-14.82M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
0.75M0.75M11.00M
Non-Current Debt
-0.75M-0.75M-11.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.75M-0.75M-11.00M
Change in Capital Stock
Common Stock IssuedStock Issued
0.75M0.26M0.26M0.21M0.05M0.06M0.00M0.52M0.14M0.01M0.11M0.11M0.61M33.73M
Shares Repurchased
0.09M0.02M0.11M0.09M0.16M0.02M0.01M0.20M
Net Shares Issued and RepurchasedNet Shares Issued
0.75M0.26M0.26M0.21M0.05M-0.04M0.00M-0.02M0.41M0.14M-0.07M0.11M-0.16M0.08M-0.01M0.41M33.73M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.75M0.26M0.26M0.21M0.05M-0.04M0.00M-0.02M0.41M0.14M-0.07M0.11M-0.16M0.08M-0.01M0.41M33.73M
Other financing activitiesOther financing
0.18M-0.29M0.22M0.15M0.10M0.00M0.26M0.00M0.08M0.30M0.00M0.11M0.16M0.00M0.06M
Cash from Financing ActivitiesCash from Financing
0.58M0.47M0.48M0.26M0.36M0.05M-0.68M-0.75M-10.75M57.67M34.58M0.14M10.51M0.11M-0.05M7.77M118.67M0.46M33.73M
Additional items
Change in Cash
-118.40M-84.62M-30.12M11.29M-7.75M-19.80M19.72M-4.60M16.27M65.61M-36.93M-16.55M-13.47M-4.15M-4.21M26.86M-19.35M15.79M-13.33M17.34M
Ending Cash Balance
164.02M79.40M49.28M60.58M52.83M33.03M52.76M48.16M64.43M130.03M93.10M76.56M63.09M58.94M54.74M81.60M62.25M78.05M64.72M82.05M
Free Cash FlowFCF
-18.36M-25.78M-26.77M-22.72M-31.33M-30.62M-33.71M-19.36M-31.31M-24.17M-18.12M-5.17M-24.12M-17.93M-33.29M-12.24M-31.62M-22.16M-30.01M-1.61M
Net Cash FlowNCF
-118.40M-84.62M-30.12M11.29M-7.75M-19.80M19.72M-4.60M16.27M65.61M-36.93M-16.55M-13.47M-4.15M-4.21M26.86M-19.35M15.79M-13.33M17.34M
Interest Paid
0.36M0.24M0.47M0.36M0.38M0.42M0.43M0.42M0.14M

C4 Therapeutics Cash Flow Statement API

Pull C4 Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CCCC&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY